FDA Extends Safety Review of Mifepristone Abortion Medication

The U.S. FDA announced its safety review of mifepristone, a primary medication used for abortion, will continue into next year, drawing criticism from abortion opponents. This update, provided in a court-ordered legal filing, follows a reevaluation initiated by Health Secretary Robert F. Kennedy Jr. The agency expects to finalize a safety study by mid-December 2026, with a report on its findings anticipated no later than March 2027, after which decisions on potential restrictions will be made.